Clinical Data Beam one-ups Wave as both show promise of genetic editing for AATD BioSpaceWhile both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 antitrypsin deficiency assets,...Rare DiseaseRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) BioSpace While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 antitrypsin deficiency assets,… Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Parabilis follows hefty Regeneron deal with IPO pushNext: Pepaxti study supports use in wider myeloma population Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
